People with inflammatory bowel disease (IBD) or Parkinson’s disease have depletions in similar types of beneficial bacteria, ...

Parkinson’s Disease (PD) is one of the most common brain disorders linked to aging, affecting movement and often leading to ...

Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by motor symptoms such as bradykinesia, rigidity, and tremor, alongside a ...

April marks Parkinson's Disease Awareness Month, and the American Parkinson Disease Association (APDA) is launching a ...

MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS), a clinical-stage biopharmaceutical company, is set to showcase significant ...

Through a pioneering initiative called Chronos-PD, Grifols is partnering with the Michael J. Fox Foundation for Parkinson’s ...

April has been designated Parkinson's disease (PD) awareness month.

Compelling preclinical data in models of both GBA1-PD and idiopathic PD, demonstrating a disease-modifying effect after ...

Favorable initial results from a phase 1/2 trial of solnerstotug in PD-L1–resistant tumors showed a 14% response rate and 62% ...

Annovis Bio Inc. (NYSE: ANVS) ("Annovis"), a late-stage clinical drug platform company pioneering transformative therapies ...

Medication options are available to help manage the cognitive and behavioral symptoms of dementia and Alzheimer's disease.

Sensei Biotherapeutics' solnerstotug shows a 14% ORR in PD-(L)1 resistant tumors and remains well tolerated in early trial data from its Phase 1/2 study.